Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis

BACKGROUND/AIM: Presently, there are no therapeutic options for unresectable hepatocellular carcinoma (u‐HCC) patients who are intolerant to sorafenib or regorafenib failure. There have been no reports with detailed clinical findings of lenvatinib (LEN), a newly developed first‐line tyrosine kinase...

詳細記述

保存先:
書誌詳細
出版年:Cancer Med
主要な著者: Hiraoka, Atsushi, Kumada, Takashi, Kariyama, Kazuya, Takaguchi, Koichi, Atsukawa, Masanori, Itobayashi, Ei, Tsuji, Kunihiko, Tajiri, Kazuto, Hirooka, Masashi, Shimada, Noritomo, Shibata, Hiroshi, Ishikawa, Toru, Ochi, Hironori, Tada, Toshifumi, Toyoda, Hidenori, Nouso, Kazuhiro, Tsutsui, Akemi, Itokawa, Norio, Imai, Michitaka, Joko, Kouji, Hiasa, Yoichi, Michitaka, Kojiro
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2018
主題:
Clinical Cancer Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6346240/
https://ncbi.nlm.nih.gov/pubmed/30575325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1909
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料